癌症单株抗体市场 - 全球产业规模、份额、趋势、机会及预测（按单株抗体类型、单株抗体疗法、应用、地区和竞争格局划分，2021-2031年）

全球癌症单株抗体市场预计将从 2025 年的 996.6 亿美元成长到 2031 年的 2,449.5 亿美元，复合年增长率为 16.17%。

这些实验室设计的分子透过与癌细胞上的特定抗原结合发挥作用，有效促进免疫系统清除肿瘤细胞或抑制细胞生长讯号。恶性肿瘤在全球日益普遍，推动了这个产业的发展，使得生物目标疗法的研发至关重要。美国癌症协会估计，光是2025年，美国就将新增2,041,910例癌症病例，凸显了该领域的迫切性。日益加重的患者负担，加上免疫疗法药物审批流程的加快，为该领域的蓬勃发展奠定了基础。

儘管成长指标强劲，但由于生物製药的研发和收购成本高昂，市场仍面临许多障碍。高昂的生产资本往往导致价格上涨，限制了发展中地区的病患获取，并给医疗报销体系带来巨大压力。因此，严格的定价监管和高品质免疫疗法的保险覆盖不足仍然是限制这些先进治疗方法市场渗透率和商业性扩充性的重要障碍。

市场驱动因素

抗体工程技术的快速发展，特别是从标准单株抗体转向高效抗体药物复合体（ADC）和双特异性抗体构建体的转变，是推动市场发展的关键因素。这些先进的技术能够将细胞毒性有效载荷精准地递送至癌细胞，同时最大限度地降低全身毒性，有效克服了传统疗法的疗效局限性和抗药性问题。这项技术进步促成了重大的策略整合，各公司纷纷寻求收购独特的平台以增强其产品组合。例如，强生公司于2024年3月宣布，已完成与Ambrax公司的全现金合併（总对价约20亿美元），旨在整合其针对转移性前列腺癌和其他固体癌的下一代ADC产品组合。这凸显了业界向具有卓越治疗特性的复杂生物製药转型的趋势。

第二个关键驱动因素是肿瘤研发和生产基础设施投资的激增，以支持临床管线和商业供应链。製药开发商正投入大量资金建造端到端的生产设施，以确保这些复杂药物的稳定供应。一个显着的例子是Astra Zeneca于2024年5月宣布的15亿美元资本投资计划，用于在新加坡新建一座专门用于生产抗体药物复合体的待开发区生产工厂。这股资金涌入主要源自于关键疗法的巨大收入潜力。默克截至2024年2月的财年财务表现显示，其旗舰抗体药物Keytruda的销售额成长了19%，达到250亿美元，证实了该领域投资的强劲回报。

市场挑战

开发和取得抗癌单株抗体的高昂成本是其市场持续扩张的一大障碍。由于这些生物製药的生产过程复杂，且需要经过严格的临床试验，其定价通常超出医疗体系的承受能力，尤其是在开发中国家。面对如此高昂的成本，支付方和保险公司往往会设定严格的报销标准和处方集限制。这限制了符合这些救命疗法适用条件的患者群体，直接降低了关键国际市场的商业性销售量，并阻碍了收入成长。

根据国际药物经济学与结果研究协会（ISPOR）2024年的数据，特定先进免疫疗法的单疗程费用已高达约31.8万美元。如此高昂的价格给患者造成了沉重的经济负担（经济毒性），也给国家医疗预算带来了难以承受的压力。因此，在对成本敏感的地区，市场难以实现广泛渗透，因为这种经济压力迫使医疗政策制定者对治疗进行发行或推迟高成本生物製药的引入，从而有效地阻碍了该行业的潜在发展势头。

市场趋势

随着现有单株抗体专利的到期，市场正经历着向癌症生物相似药商业化的重大转变。这一趋势使医疗系统能够采用成本效益更高的替代方案，这些方案既能保持临床疗效，又能缓解预算限制，从而扩大患者获得必要生物疗法的机会。製造商正积极拓展产品系列，以期在这个高销售细分市场中占据份额，挑战原厂药的主导地位。例如，山德士公司报告称，截至2024年3月的财年，其生物製药业务净销售额增长15%，达到22亿美元，这主要得益于生物类似药在全球范围内的持续普及。

同时，製药公司正优先开发皮下製剂，以取代传统的静脉输注，用于已建立的癌症疗法。这种改良策略旨在减轻输液中心的后勤负担，并透过显着缩短给药时间来提高患者的便利性。利用专有的酵素技术增强吸收，研发人员能够透过快速注射而非长时间输注的方式给药高剂量生物製药製剂。根据2024年9月的新闻稿（宣布基因泰克公司的TECENTRIQ Hybreza获得FDA核准），这种新核准的皮下给药方式将给药时间缩短至约7分钟，而标准静脉注射通常需要30至60分钟。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球癌症单株抗体市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 单株抗体类型（鼠源抗体、嵌合体抗体、人源化抗体）
  • 透过单株抗体疗法（Bevacizumab（Avastin）、Rituximab（Rituxan）、曲妥珠单抗（Herceptin）、Cetuximab（爱必妥）、Panitumumab（Vectibix）等）
  • 依应用领域（乳癌、血癌、肝癌、脑瘤、结肠癌等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美癌症单株抗体市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲癌症单株抗体市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区癌症单株抗体市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲癌症单株抗体市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美癌症单株抗体市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球癌症单株抗体市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche Ltd
• Genmab AS
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Merck & Co., Inc
• Spectrum Pharmaceuticals Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cancer Monoclonal Antibodies Market is projected to expand from USD 99.66 Billion in 2025 to USD 244.95 Billion by 2031, reflecting a compound annual growth rate of 16.17%. These laboratory-engineered molecules function by binding to specific antigens on tumor cells, effectively flagging them for immune system elimination or inhibiting cell growth signals. The industry is primarily driven by the escalating global prevalence of malignancies, which necessitates the creation of targeted biologic therapies. Highlighting this urgent need, the American Cancer Society estimates that there will be 2,041,910 new cancer diagnoses in the United States alone in 2025. This increasing patient burden, combined with expedited regulatory pathways for immunotherapy agents, serves as a fundamental pillar supporting the sector's upward trajectory.

Despite these strong growth indicators, the market confronts significant obstacles due to the immense costs involved in the development and acquisition of these biologics. High production capital often results in elevated pricing structures, which limits accessibility in developing regions and places considerable strain on healthcare reimbursement systems. Consequently, strict pricing regulations and inadequate insurance coverage for premium immunotherapies persist as substantial barriers, potentially restricting the broader market penetration and commercial scalability of these advanced treatments.

Market Driver

A primary market driver is the rapid evolution of antibody engineering, specifically the transition from standard monoclonal antibodies to highly potent antibody-drug conjugates (ADCs) and bispecific constructs. These advanced modalities enable the precise delivery of cytotoxic payloads to tumor cells while minimizing systemic toxicity, effectively addressing past efficacy limitations and resistance issues. This technological progression is triggering major strategic consolidations as companies aim to acquire proprietary platforms to strengthen their portfolios. For instance, Johnson & Johnson announced in March 2024 that it had finalized an all-cash merger valued at approximately $2.0 billion with Ambrx to integrate a suite of next-generation ADCs targeting metastatic prostate cancer and other solid tumors, underscoring the industry's shift toward complex biologics with superior therapeutic profiles.

A second critical catalyst is the surging investment in oncology research and manufacturing infrastructure to support clinical pipelines and commercial supply chains. Pharmaceutical developers are dedicating substantial capital to establishing end-to-end production facilities to ensure the availability of these intricate drugs. A clear example of this is AstraZeneca's announcement in May 2024 regarding a capital expenditure of $1.5 billion to construct a greenfield manufacturing plant in Singapore dedicated to antibody-drug conjugates. This financial influx is heavily incentivized by the immense revenue potential of leading therapies; according to Merck & Co.'s February 2024 financial results, sales of their flagship antibody Keytruda grew by 19% to reach $25.0 billion, confirming the high return on investment available within this sector.

Market Challenge

The steep costs required to develop and acquire cancer monoclonal antibodies create a formidable barrier to the market's continued expansion. These biologic therapies involve complex manufacturing processes and rigorous clinical testing, resulting in high pricing structures that often exceed the financial capabilities of healthcare systems, particularly in developing nations. When payers and insurance providers face such elevated expenses, they frequently enforce strict reimbursement criteria or limit formulary inclusion. This restricts the patient population eligible for these life-saving treatments, directly reducing commercial volumes and hampering revenue growth in key international territories.

Data from the International Society for Pharmacoeconomics and Outcomes Research in 2024 indicates that the cost for a single course of certain advanced immunotherapy regimens has reached approximately $318,000. Such elevated price points generate severe financial toxicity for patients and impose unsustainable burdens on national health budgets. Consequently, the market struggles to achieve broad penetration in cost-sensitive regions, as this economic pressure compels healthcare decision-makers to ration care or delay the adoption of premium biologic agents, effectively stalling the industry's potential momentum.

Market Trends

The market is currently experiencing a significant shift toward the commercialization of oncology biosimilars as patents for legacy monoclonal antibodies begin to expire. This trend enables healthcare systems to adopt cost-effective alternatives that preserve clinical efficacy while mitigating budget constraints, thereby broadening patient access to essential biologic therapies. Manufacturers are aggressively expanding their portfolios to capture market share in this high-volume segment, challenging the dominance of originator drugs. For example, Sandoz reported in its March 2024 results that net sales for its biopharmaceuticals business grew by 15% to reach USD 2.2 billion, a performance largely driven by the continued global uptake of its biosimilar assets.

Simultaneously, pharmaceutical entities are prioritizing the development of subcutaneous formulations to replace traditional intravenous infusions for established cancer therapies. This reformulation strategy aims to alleviate the logistical burden on infusion centers and enhance patient convenience by drastically reducing the time required for treatment administration. By utilizing proprietary enzyme technologies to facilitate absorption, developers can deliver large-volume biologics via rapid injection rather than prolonged infusion. According to a September 2024 press release regarding the FDA approval of Genentech's Tecentriq Hybreza, this newly approved subcutaneous option reduces administration time to approximately seven minutes, compared to the 30 to 60 minutes typically required for standard intravenous delivery.

Key Market Players

• Amgen Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche Ltd
• Genmab AS
• GlaxoSmithKline PLC
• Johnson & Johnson
• Novartis AG
• Merck & Co., Inc
• Spectrum Pharmaceuticals Inc

Report Scope

In this report, the Global Cancer Monoclonal Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Monoclonal Antibodies Market, By Type of Monoclonal Antibody

• Murine Antibodies
• Chimeric Antibodies
• Humanized Antibodies

Cancer Monoclonal Antibodies Market, By Monoclonal Antibody Therapies

• Bevacizumab (Avastin)
• Rituximab (Rituxan)
• Trastuzumab (Herceptin)
• Cetuximab (Erbitux)
• Panitumumab (Vectibix)
• Other

Cancer Monoclonal Antibodies Market, By Application

• Breast Cancer
• Blood Cancer
• Liver Cancer
• Brain Cancer
• Colorectal Cancer
• Other

Cancer Monoclonal Antibodies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Monoclonal Antibodies Market.

Available Customizations:

Global Cancer Monoclonal Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Monoclonal Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Monoclonal Antibody (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies)
  • 5.2.2. By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other)
  • 5.2.3. By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Cancer Monoclonal Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Monoclonal Antibody
  • 6.2.2. By Monoclonal Antibody Therapies
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Monoclonal Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Monoclonal Antibody
      • 6.3.1.2.2. By Monoclonal Antibody Therapies
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Cancer Monoclonal Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Monoclonal Antibody
      • 6.3.2.2.2. By Monoclonal Antibody Therapies
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Cancer Monoclonal Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Monoclonal Antibody
      • 6.3.3.2.2. By Monoclonal Antibody Therapies
      • 6.3.3.2.3. By Application

7. Europe Cancer Monoclonal Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Monoclonal Antibody
  • 7.2.2. By Monoclonal Antibody Therapies
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cancer Monoclonal Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Monoclonal Antibody
      • 7.3.1.2.2. By Monoclonal Antibody Therapies
      • 7.3.1.2.3. By Application
  • 7.3.2. France Cancer Monoclonal Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Monoclonal Antibody
      • 7.3.2.2.2. By Monoclonal Antibody Therapies
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Cancer Monoclonal Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Monoclonal Antibody
      • 7.3.3.2.2. By Monoclonal Antibody Therapies
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Cancer Monoclonal Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Monoclonal Antibody
      • 7.3.4.2.2. By Monoclonal Antibody Therapies
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Cancer Monoclonal Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Monoclonal Antibody
      • 7.3.5.2.2. By Monoclonal Antibody Therapies
      • 7.3.5.2.3. By Application

8. Asia Pacific Cancer Monoclonal Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Monoclonal Antibody
  • 8.2.2. By Monoclonal Antibody Therapies
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cancer Monoclonal Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Monoclonal Antibody
      • 8.3.1.2.2. By Monoclonal Antibody Therapies
      • 8.3.1.2.3. By Application
  • 8.3.2. India Cancer Monoclonal Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Monoclonal Antibody
      • 8.3.2.2.2. By Monoclonal Antibody Therapies
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Cancer Monoclonal Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Monoclonal Antibody
      • 8.3.3.2.2. By Monoclonal Antibody Therapies
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Cancer Monoclonal Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Monoclonal Antibody
      • 8.3.4.2.2. By Monoclonal Antibody Therapies
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Cancer Monoclonal Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Monoclonal Antibody
      • 8.3.5.2.2. By Monoclonal Antibody Therapies
      • 8.3.5.2.3. By Application

9. Middle East & Africa Cancer Monoclonal Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Monoclonal Antibody
  • 9.2.2. By Monoclonal Antibody Therapies
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cancer Monoclonal Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Monoclonal Antibody
      • 9.3.1.2.2. By Monoclonal Antibody Therapies
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Cancer Monoclonal Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Monoclonal Antibody
      • 9.3.2.2.2. By Monoclonal Antibody Therapies
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Cancer Monoclonal Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Monoclonal Antibody
      • 9.3.3.2.2. By Monoclonal Antibody Therapies
      • 9.3.3.2.3. By Application

10. South America Cancer Monoclonal Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Monoclonal Antibody
  • 10.2.2. By Monoclonal Antibody Therapies
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cancer Monoclonal Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Monoclonal Antibody
      • 10.3.1.2.2. By Monoclonal Antibody Therapies
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Cancer Monoclonal Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Monoclonal Antibody
      • 10.3.2.2.2. By Monoclonal Antibody Therapies
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Cancer Monoclonal Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Monoclonal Antibody
      • 10.3.3.2.2. By Monoclonal Antibody Therapies
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cancer Monoclonal Antibodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Amgen Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol Myers Squibb Company
• 15.3. Eli Lilly and Company
• 15.4. Hoffmann-La Roche Ltd
• 15.5. Genmab AS
• 15.6. GlaxoSmithKline PLC
• 15.7. Johnson & Johnson
• 15.8. Novartis AG
• 15.9. Merck & Co., Inc
• 15.10. Spectrum Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer